Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ferozsons LaboratoriesKAR:FEROZ +1.38%70 Days Payable is 141.48 as of Mar. 2026, which is 99% above its 10-year median of 71.26. GuruFocus rates KAR:FEROZ with a GF Score™ of 70/100 and a GF Value™ of ₨420.46 (Fairly Valued). The stock has 4 warning signs investors should review. Among 927 Drug Manufacturers companies, Ferozsons Laboratories ranks better than 60.63% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
KAR:FEROZ vs ZTS, UTHR, VTRS: Days Payable Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Ferozsons Laboratories's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ferozsons Laboratories Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Ferozsons Laboratories's Days Payable distribution charts can be found below:
* The bar in red indicates where Ferozsons Laboratories's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Ferozsons Laboratories's Days Payable for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ferozsons Laboratories (KAR:FEROZ) has a Days Payable of 141.48 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Ferozsons Laboratories and its competitors. This is 99% above median its historical median of 71.26. Over the past decade, Ferozsons Laboratories' Days Payable has ranged from 51.35 to 110.89. According to the industry distribution chart, Ferozsons Laboratories ranks #365 out of 927 companies in the Drug Manufacturers industry, placing it in the top 39.4%.
Is Ferozsons Laboratories' Days Payable too high?
Ferozsons Laboratories' current Days Payable of 141.48 is 99% above median its 10-year median of 71.26. Over the past 10 years, this metric has ranged from a low of 51.35 to a high of 110.89. The Drug Manufacturers industry median Days Payable is 90.38. Ferozsons Laboratories' value of 141.48 is 56.5% above this industry median. Based on the distribution chart, Ferozsons Laboratories ranks #365 out of 927 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Ferozsons Laboratories has a GF Score™ of 70/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Ferozsons Laboratories' Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Ferozsons Laboratories ranks #365 out of 927 companies for Days Payable. This puts Ferozsons Laboratories in the upper half of its industry. The industry median Days Payable is 90.38. Ferozsons Laboratories' value of 141.48 is 56.5% above this benchmark. Historically, Ferozsons Laboratories' own Days Payable has ranged from 51.35 to 110.89 over the past decade. While the company's 10-year median is 71.26 vs. the industry median of 90.38, Ferozsons Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.38, based on 927 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ferozsons Laboratories's current Days Payable of 141.48 is 56.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Ferozsons Laboratories and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ferozsons Laboratories's current Days Payable is 141.48, which is 99% above median its own 10-year median of 71.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ferozsons Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Ferozsons Laboratories (KAR:FEROZ) is currently considered Fairly Valued. The stock's GF Value™ is ₨420.46, compared to a current price of ₨385.47 — trading 8.3% below its estimated fair value. The current Days Payable is 141.48, which is 99% above median its 10-year median of 71.26 and 56.5% above the Drug Manufacturers industry median of 90.38. Ferozsons Laboratories' overall GF Score™ is 70/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Ferozsons Laboratories (KAR:FEROZ), the current Days Payable is 141.48 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ferozsons Laboratories (KAR:FEROZ) Overvalued in 2026?
Based on GuruFocus' analysis, Ferozsons Laboratories stock appears to be undervalued.
The current stock price of ₨385.47 is trading 8.3% below its estimated GF Value™ of ₨420.46.
GuruFocus considers Ferozsons Laboratories to be Fairly Valued.
Key valuation signals for KAR:FEROZ:
Days Payable: 141.48 (99% above median its 10-year median of 71.26)
GF Value™: ₨420.46 vs. price of ₨385.47 (8.3% below fair value)
Industry Position: 56.5% above the Drug Manufacturers median (#365 of 927)
No single metric tells the full story. See the KAR:FEROZ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ferozsons Laboratories Ltd is a pharmaceutical company. It is engaged in the import, manufacture, and sale of pharmaceuticals products and medical devices. The company operates in the therapeutic areas of dermatology, anti-infective treatments, gastroenterology, hepatology, cardiology, and diabetes. It manufactures tablets, capsules, syrups, suspensions, creams, and ointments. The company operates in three segments namely Ferozsons, BF Biosciences, and Others. The group sells its products in Pakistan and internationally, of which the majority of the revenue is generated from the sales made in Pakistan.
70GF Score
Get the complete analysis for KAR:FEROZ
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KAR:FEROZ has been successfully added to your 
